Visus Therapeutics
17 articles with Visus Therapeutics
-
Visus Therapeutics Appoints World-Renowned Ophthalmologist, Eric D. Donnenfeld, M.D., to Board of Directors
1/11/2023
Visus Therapeutics Inc. today announced the appointment of Eric D. Donnenfeld, M.D., to the Company’s Board of Directors.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
-
Opthalmology Space Gains Clarity with Partnerships & Acquisitions by Outlook & Visus Therapeutics
9/28/2022
A cloudy ophthalmic space got a little clearer Wednesday with the two collaborations by Visus Therapeutics and Outlook Therapeutics, now preparing for FDA approval. -
Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets
9/28/2022
Visus Therapeutics Inc. today announced it has expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics.
-
Visus Therapeutics to Present at the Baird 2022 Global Healthcare Conference
9/7/2022
Visus Therapeutics, Inc. announced that Ben Bergo, co-founder and chief executive officer, will present at the Baird 2022 Global Healthcare Conference on September 13th, 2022, at the InterContinental New York Barclay hotel.
-
Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia
5/11/2022
Visus Therapeutics, Inc. and Zhaoke Ophthalmology Limited announced an exclusive licensing agreement for the development and commercialization of BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and select Southeast Asian territories.
-
Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting
4/27/2022
Visus Therapeutics Inc. today announced that it will present new scientific data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting , to be held May 1-4, 2022 in Denver, Colorado.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL™ PF for the Treatment of Presbyopia
3/22/2022
Visus Therapeutics Initiates Phase 3 Pivotal Trials of BRIMOCHOL ™ PF for the Treatment of Presbyopia.
-
Visus Therapeutics Announces Appointment of Eye Care Industry Veteran Julia Williams as Vice President of Clinical and Medical Affairs and Expansion of Irvine Co-Headquarters
3/16/2022
Visus Therapeutics Inc. today announced the appointment of eye care industry veteran Julia Williams as vice president of clinical and medical affairs.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia
11/30/2021
Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia.
-
Visus Therapeutics Appoints Ophthalmology Expert David Guyer, M.D., as Chairman of the Board and Welcomes Seasoned Life Sciences Executive Ted Danse as Head of Business Development
11/3/2021
Visus Therapeutics Inc. today announced the appointment of ophthalmology and industry expert David Guyer, M.D. as the chairman of the Board
-
Visus Therapeutics Expands Ophthalmic Drug Portfolio With Investigational Therapies for Glaucoma and Age-related Macular Degeneration; Secures Exclusive License for Novel Ophthalmic Drug Delivery Technology
8/19/2021
Visus Therapeutics Inc. announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration, two of the leading causes of blindness globally.
-
Visus Therapeutics has acquired an additional $20 million in funding to support its mission of developing innovative ophthalmic therapies for people worldwide.
-
Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drop
3/9/2021
Visus Therapeutics Inc. today announced the close of a $36 million Series A Preferred Stock financing. Johnson & Johnson Innovation - JJDC, Inc. (JJDC), RTW Investments, LP, and Wille AG participated in the round, with additional participation from the Company’s existing shareholders